| Today's Date: Monday, February 08, 2010 |
| Contraceptive Ring Enters Testing For HIV Prevention |
| Wednesday, May 20, 2009 |
| The new device is a vaginal ring that releases multiple types of non-hormonal agents and microbicides, which would prevent conception as well as sexually transmitted HIV infection.
Worldwide, there are about 5 million new infections and 3 million deaths per year due to HIV/AIDS. If proven successful in future clinical trials, the new device could provide women with the stone to kill two birds – protecting themselves from unintended pregnancy and sexually transmitted infection (STI). The ring may also someday represent a novel method to prevent STIs for those with aversion to currently available methods, with hormonally derived active agents, or with allergies to latex condoms, researchers said. "This device is a new approach to birth control, because it avoids the long-term use of hormonal methods that have been associated with increased risk of certain cancers," said Dr. Brij Saxena, lead author and the Harold and Percy Uris Professor of Reproductive Biology and professor of endocrinology in the Department of Obstetrics and Gynecology at Weill Cornell Medical College. "At the same time, this is the first device to simultaneously offer the possibility to prevent unintended pregnancy and HIV transmission." "No one has ever conquered a viral epidemic with treatment, so prevention is the most effective option. Ideally, an HIV vaccine is the most desirable method, but that is not foreseeable in the near future," explained Dr. Jeffrey Laurence, co-author of the study and attending physician at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. "The next best thing would be something that would prevent infection and put the power in the susceptible female partner's control. That's the potential a device such as this can offer." The vaginally inserted ring is incorporated with multiple antiviral drugs that prevent HIV infection and are time-released over a period up to 28 days. The compounds tested were a newly developed anti-HIV agent, Boc-lysinated betulonic acid, TMC120 (dapivirine), PMPA, and 3'-azido-3'-deoxythymidine (AZT or zidovudine), which, when combined, were found to block infection in human cells exposed to the virus in a laboratory setting, researchers said. "The combination of these antiviral drugs has proven to be potent agents that may block infection by the HIV virus," said Saxena. The ring is also incorporated with compounds that prevent conception by arresting sperm motility, raising vaginal mucous viscosity, and sustaining the acidity of the vagina in which sperm do not survive. Traditionally, similar devices have used hormonal compounds that have been linked to increased risk of breast and cervical cancers, or spermicidal compounds that kill sperm, but may lead to irritation and inflammation. Past findings published in the journal Contraception found the device to be highly effective in animal models and in laboratory testing, said researchers. "The compounds in the device are natural materials that are already approved by the U.S. Food and Drug Administration for use in humans," explained Saxena. The study was supported by grants by the National Institutes of Health, International Partnership for Microbicides and BioRing LLC, and published in the journal AIDS. For more information, visit www.med.cornell.edu. |
This site serves executives who are responsible for the management and administration of women's health programs. Our community includes hospital women's health managers, as well as directors and managers of women's health programs of government agencies, other healthcare organizations, health insurance plans, women's health organizations, colleges and universities and community-based organizations.
Click here to Contact Us
